TITLE

Recently Approved

PUB. DATE
September 2005
SOURCE
Pharmaceutical Representative;Sep2005, Vol. 35 Issue 9, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Lists drugs approved by the United States Food and Drug Administration as of September 2005. QLT Inc.'s Aczone (dapsone) gel for the topical treatment of acne vulgaris; Shire Pharmaceuticals' Adderall XR for the treatment of patients ages 13 to 17 with attention deficit-hyperactivity disorder; Pfizer Inc.'s Celebrex (celecoxib) for the relief of the signs and symptoms of ankylosing spondylitis.
ACCESSION #
18123564

 

Related Articles

  • COMPANY SPOTLIGHT - Shire Pharmaceuticals.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p17 

    This article presents information related to the business and research activities of Shire Pharmaceuticals Inc. The U.S. FDA has approved Shire's Adderall XR to be used in the treatment of attention deficit hyperactivity disorder in adolescents aged 13 to 17. The FDA based its approval on data...

  • Shire Withdraws US Bid For Fabry Drug.  // MondayMorning;3/19/2012, Vol. 20 Issue 12, p1 

    The article presents information on Shire Pharmaceuticals Group Plc. which has withdrawn its bid for the drug Replagal Biologic, which is used to treat a genetic disorder called Fabry disease, for the U.S. Food and Drug Administration (FDA) approval. Shire has issued a statement according to...

  • product showcase.  // Pharmacy Today;Sep2011, Vol. 17 Issue 9, p38 

    The article offers several information related to drug approval in the U.S. in 2011. The Food and Drug Administration (FDA) revealed the approval of the 2011-2012 influenza vaccines. Merz Aesthetics revealed the approval of incobotulinumtoxin A (Xeomin) by the FDA for temporary improvement of...

  • Pfizer submits new drug application requesting changes in Geodon product label.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p11 

    Focuses on the supplemental new drug application submitted by Pfizer Inc. to the U.S. Food and Drug Administration requesting changes in the product label information for Geodon. Inclusion of Geodon's lack of adverse effects on blood lipids and glycemic control; Flexibility of dosage;...

  • PRIMING THE PIPELINE. McGuire, Stephen // Medical Marketing & Media;Dec2004, Vol. 39 Issue 12, p42 

    The article informs that as of September 30, U.S. Food & Drug Administration had approved 16 new molecular entities and 69 new drug applications compared with 21 and 72, respectively, for all of 2003. Hardly a robust year for approvals, then, but on course for a slight improvement. Pfizer Inc....

  • Pipeline.  // Medical Marketing & Media;Jan2009, Vol. 44 Issue 1, p10 

    The article offers news briefs related to medicine in the U.S. The Food and Drug Administration (FDA) approved Pfizer Inc.'s Selzentry tablets. FDA approved Schering-Plough to market its hepatitis C combination therapy consisting Pegintron and Rebetol. The Boostrix vaccine of GlaxoSmithKline was...

  • SHIRE GETS FDA APPROVABLE LETTER FOR DAYTRANA FOR ADHD.  // Worldwide Biotech;Feb2006, Vol. 18 Issue 2, p3 

    Reports on the approval given by the U.S. Food and Drug Administration to DAYTRANA, an investigational methylphenidate transdermal system developed by Shire PLC. Use of the drug for treating attention deficit hyperactivity disorder (ADHD) in children; Remarks from company CEO Matthew Emmens...

  • Opinion: Shire: Intuniv approval diversifies ADHD portfolio.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p14 

    The author focuses on the announcement of Shire Pharmaceuticals Group PLC on the approval by the Food & Drug Administration (FDA) of the Intuniv extended release tablets for the treatment of attention-deficit hyperactivity disorder (ADHD). It notes that Intuniv represents Shire's first venture...

  • Renovo Licenses Juvista To Shire In $825M Deal.  // Bioworld Week;6/25/2007, Vol. 15 Issue 26, p5 

    The article reports on the partnership of Renovo Group PLC and Shire PLC for dealing with the anti-scarring drug Juvista in 2007. Shire has won out by offering a package that includes $125 million up front, which is $75 million in cash and $50 million in equity purchased at $3.97 per share....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics